Mucoepidermoid carcinoma of the breast: Four case reports and review of the literature

por Cheng, Meng, Geng, Cuizhi, Tang, Tiantian, Song, Zhenchuan
Publicado 2017

Molecular Modification of Metadherin/MTDH Impacts the Sensitivity of Breast Cancer to Doxorubicin

por Song, Zhenchuan, Wang, Yong, Li, Chao, Zhang, Donghong, Wang, Xinle
Publicado 2015

Prognostic Impact of Progesterone Receptor Status in Chinese Estrogen Receptor Positive Invasive Breast Cancer Patients

por Yao, Nan, Song, Zhenchuan, Wang, Xinle, Yang, Shan, Song, Heng
Publicado 2017

Research on shifting process control of automatic transmission

por Zou, Wujun, Wang, Ye, Zhong, Chaojie, Song, Zhenchuan, Li, Shenlong
Publicado 2022

Metformin improves the outcomes in Chinese invasive breast cancer patients with type 2 diabetes mellitus

por Hui, Tianli, Shang, Chao, Yang, Liu, Wang, Meiqi, Li, Ruoyang, Song, Zhenchuan
Publicado 2021

miR-217-5p suppresses epithelial-mesenchymal transition and the NF-κB signaling pathway in breast cancer via targeting of metadherin

por Yang, Lixian, Liu, Shuo, Yang, Liu, Xu, Bin, Wang, Meiqi, Kong, Xiangshun, Song, Zhenchuan
Publicado 2022

Elevated expression of MTDH predicts better prognosis of locally advanced HER-2 positive breast cancer patients receiving neoadjuvant chemotherapy plus trastuzumab

por Wang, Xinle, Cai, Lijing, Ye, Feng, Li, Mengqi, Ma, Li, Geng, Cuizhi, Song, Zhenchuan, Liu, Yueping
Publicado 2019

Exploring risk factors for totally implantable venous access devices (TIVADs)-related thrombotic occlusion in the off-treatment period

por Liu, Lei, Liu, Zhanlun, Wang, Jianxin, Cheng, Meng, Xie, Yanli, Wang, Weina, Ma, Cuicui, Zhang, Lina, Song, Zhenchuan, Zhang, Yanshou
Publicado 2023

Pegylated liposomal doxorubicin plus cyclophosphamide followed by docetaxel as neoadjuvant chemotherapy in locally advanced breast cancer (registration number: ChiCTR1900023052)

por Li, Ruoyang, Tian, Fuguo, Qi, Yixin, Ma, Li, Zhou, Tao, Li, Yuntao, Hui, Tianli, Zhang, Lina, Wang, Shuo, Song, Zhenchuan
Publicado 2019

Pegylated Liposomal Doxorubicin, Docetaxel, and Trastuzumab as Neoadjuvant Treatment for HER2-Positive Breast Cancer Patients: A Phase II and Biomarker Study

por Wang, Haoqi, Li, Yuntao, Qi, Yixin, Zhao, Erbao, Kong, Xiangshun, Yang, Chao, Yang, Qiqi, Zhang, Chengyuan, Liu, Yueping, Song, Zhenchuan
Publicado 2022

Monitoring circulating platelet activity to predict cancer-associated thrombosis

por Li, Bozhao, Lu, Zefang, Yang, Zhenlin, Zhang, Xiuping, Wang, Meiqi, Chu, Tianjiao, Wang, Peina, Qi, Feilong, Anderson, Greg J., Jiang, Ershuai, Song, Zhenchuan, Nie, Guangjun, Li, Suping
Publicado 2023

Pyrotinib plus capecitabine for trastuzumab-resistant, HER2-positive advanced breast cancer (PICTURE): a single-arm, multicenter phase 2 trial

por Cao, Jun, Teng, Yuee, Li, Huiping, Zhang, Lili, Ouyang, Quchang, Xie, Weimin, Pan, Yueyin, Song, Zhenchuan, Ling, Xiaoling, Wu, Xiaohong, Xu, Jingwei, Li, Li, Ren, Liping, Wang, Hong, Zhou, Dongxian, Luo, Jing, Hu, Xichun
Publicado 2023